This is a preprint.
Genetic regulation of TERT splicing contributes to reduced or elevated cancer risk by altering cellular longevity and replicative potential
- PMID: 39802763
- PMCID: PMC11722454
- DOI: 10.1101/2024.11.04.24316722
Genetic regulation of TERT splicing contributes to reduced or elevated cancer risk by altering cellular longevity and replicative potential
Update in
-
Genetic regulation of TERT splicing affects cancer risk by altering cellular longevity and replicative potential.Nat Commun. 2025 Feb 16;16(1):1676. doi: 10.1038/s41467-025-56947-y. Nat Commun. 2025. PMID: 39956830 Free PMC article.
Abstract
The chromosome 5p15.33 region, which encodes telomerase reverse transcriptase (TERT), harbors multiple germline variants identified by genome-wide association studies (GWAS) as risk for some cancers but protective for others. We characterized a variable number tandem repeat within TERT intron 6 (VNTR6-1, 38-bp repeat unit) and observed a strong association between VNTR6-1 alleles (Short: 24-27 repeats, Long: 40.5-66.5 repeats) and GWAS signals within TERT intron 4. Specifically, VNTR6-1 fully explained the GWAS signals for rs2242652 and partially for rs10069690. VNTR6-1, rs10069690 and their haplotypes were associated with multi-cancer risk and age-related telomere shortening. Both variants reduce TERT expression through alternative splicing and nonsense-mediated decay: rs10069690-T increases intron 4 retention and VNTR6-1-Long expands a polymorphic G quadruplex (G4, 35-113 copies) within intron 6. Treatment with G4-stabilizing ligands decreased the fraction of the functional telomerase-encoding TERT full-length isoform, whereas CRISPR/Cas9 deletion of VNTR6-1 increased this fraction and apoptosis while reducing cell proliferation. Thus, VNTR6-1 and rs10069690 regulate the expression and splicing of TERT transcripts encoding both functional and nonfunctional telomerase. Altered TERT isoform ratios might modulate cellular longevity and replicative potential at homeostasis and in response to environmental factors, thus selectively contributing to the reduced or elevated cancer risk conferred by this locus.
Conflict of interest statement
Competing interests None declared.
Figures
References
METHODS-ONLY REFERENCES
Publication types
Grants and funding
- 27305C0011/ES/NIEHS NIH HHS/United States
- OT2 OD033761/OD/NIH HHS/United States
- 27398C0011/ES/NIEHS NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- HHSN261200800001C/RC/CCR NIH HHS/United States
- ZIA AG000538/ImNIH/Intramural NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
- 27307C0011/ES/NIEHS NIH HHS/United States
- HHSN261201100007I/CA/NCI NIH HHS/United States
- U24 CA076518/CA/NCI NIH HHS/United States
- HHSN261201100063C/CA/NCI NIH HHS/United States
- HHSN261201100007C/HL/NHLBI NIH HHS/United States
- U24 HG011853/HG/NHGRI NIH HHS/United States
LinkOut - more resources
Full Text Sources